Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) was the target of a large increase in short interest in September. As of September 30th, there was short interest totaling 22,722 shares, an increase of 271.3% from the September 15th total of 6,119 shares. Based on an average daily trading volume, of 26,505 shares, the short-interest ratio is currently 0.9 days.
Defence Therapeutics Price Performance
Shares of OTCMKTS:DTCFF opened at $0.28 on Tuesday. Defence Therapeutics has a 12 month low of $0.25 and a 12 month high of $0.78. The company’s 50-day moving average price is $0.33 and its two-hundred day moving average price is $0.35.
About Defence Therapeutics
Defence Therapeutics Inc is a Canadian biotechnology company focused on developing drug-delivery technologies and therapeutic candidates for cancer and other serious diseases. Its work centers on the Accum platform, which is designed to improve the delivery of biologic medicines into cells and enhance the effectiveness of treatments such as vaccines, antibody-drug conjugates and immunotherapies.
The company’s development programs include AccuTOX, an oncology candidate intended to support targeted cancer treatment and immune activation, as well as AccuVAC vaccine applications designed to improve the delivery and performance of antigen-based vaccines.
See Also
- Five stocks we like better than Defence Therapeutics
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
